BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.